1. Home
  2. STXS vs MOLN Comparison

STXS vs MOLN Comparison

Compare STXS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STXS
  • MOLN
  • Stock Information
  • Founded
  • STXS 1990
  • MOLN 2004
  • Country
  • STXS United States
  • MOLN Switzerland
  • Employees
  • STXS N/A
  • MOLN N/A
  • Industry
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • MOLN
  • Sector
  • STXS Health Care
  • MOLN
  • Exchange
  • STXS Nasdaq
  • MOLN Nasdaq
  • Market Cap
  • STXS 151.3M
  • MOLN 136.1M
  • IPO Year
  • STXS 2004
  • MOLN 2021
  • Fundamental
  • Price
  • STXS $2.20
  • MOLN $3.72
  • Analyst Decision
  • STXS
  • MOLN
  • Analyst Count
  • STXS 0
  • MOLN 0
  • Target Price
  • STXS N/A
  • MOLN N/A
  • AVG Volume (30 Days)
  • STXS 288.7K
  • MOLN 1.8K
  • Earning Date
  • STXS 08-11-2025
  • MOLN 08-25-2025
  • Dividend Yield
  • STXS N/A
  • MOLN N/A
  • EPS Growth
  • STXS N/A
  • MOLN N/A
  • EPS
  • STXS N/A
  • MOLN N/A
  • Revenue
  • STXS $27,510,000.00
  • MOLN $2,525,030.00
  • Revenue This Year
  • STXS $25.90
  • MOLN N/A
  • Revenue Next Year
  • STXS $60.57
  • MOLN $866.67
  • P/E Ratio
  • STXS N/A
  • MOLN N/A
  • Revenue Growth
  • STXS 1.50
  • MOLN N/A
  • 52 Week Low
  • STXS $1.54
  • MOLN $3.36
  • 52 Week High
  • STXS $2.72
  • MOLN $12.22
  • Technical
  • Relative Strength Index (RSI)
  • STXS 52.17
  • MOLN 49.47
  • Support Level
  • STXS $2.08
  • MOLN $3.71
  • Resistance Level
  • STXS $2.36
  • MOLN $3.89
  • Average True Range (ATR)
  • STXS 0.12
  • MOLN 0.15
  • MACD
  • STXS -0.01
  • MOLN 0.01
  • Stochastic Oscillator
  • STXS 55.56
  • MOLN 41.27

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: